Posted by Adam Awdish on
Pooled Human Plasma (Blood Derived) from Innovative Research was used in the following study:
Eiji Hishinuma, Muneaki Shimada, Naomi Matsukawa, Daisuke Saigusa, Bin Li, Kei Kudo, Keita Tsuji, Shogo Shigeta, Hideki Tokunaga, Kazuki Kumada, Keigo Komine, Hidekazu Shirota, Yuichi Aoki, Ikuko N. Motoike, Jun Yasuda, Kengo Kinoshita, Masayuki Yamamoto, Seizo Koshiba, and Nobuo Yaegashi
June 30, 2021
Epithelial ovarian cancer (EOC) is a gynecological cancer with a high mortality rate, with a 5-year survival rate below 50%. Standard treatment for advanced EOC includes a combination of chemotherapy and surgery, however these treatments can vary in effectiveness from patient to patient and rely on early detection of the cancer.
Unfortunately, detection and diagnosis of this cancer is often delayed, thus creating the need for a reliable system for identifying biomarkers early on so treatment can start immediately. This study analyzed over 600 metabolites in plasma derived from 80 patients with EOC using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Their results found 77 metabolites that were significantly increased compared to control samples and 114 metabolites that were significantly decreased.
Related products available from Innovative Research also include: